Immunoassay News and Research

RSS

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

What were the SARS-CoV-2 seroprevalence estimates for industrial livestock operation workers in the USA for 2021-2022?

In a new study, researchers measured SARS-CoV-2 seroprevalence in industrial livestock operation workers of North Carolina, United States, between February 2021 and July 2022.

4 Nov 2022

Novel troponin test may help improve the treatment of heart attack patients

A new test has been developed in Turku, Finland, that helps in separating heart attack patients from those whose cardiac troponin values are elevated due to renal insufficiency.

1 Nov 2022

SARS-CoV-2 infection can affect menstruation

Researchers assess the association between SARS-CoV-2 infection and menstrual irregularities.

30 Oct 2022

What is the association of self-reported post-vaccination symptoms with anti–SARS-CoV-2 antibody response?

Researchers investigated the association of symptoms after COVID-19 vaccination with antibody responses against SARS-CoV-2.

26 Oct 2022

FebriDX point-of-care immunoassay can rapidly determine if an infection is bacterial or viral

Researchers explore whether FebriDx could differentiate between bacteria- and virus-induced immune responses during acute respiratory infection.

23 Oct 2022

Study finds memory B cell clones harbor the capacity to adopt multiple and functionally different fates in COVID-19 patients

Researchers examined single clones of SARS-CoV-2-specific memory B cells to understand their adaptability and fate.

13 Oct 2022

Radiometer strengthens its global Immunoassay Business in Turku

...

From Radiometer Medical 12 Oct 2022

Radiometer and Etiometry Announce Partnership to Enhance Neonatal Intensive Care Clinical Workflows and Patient care

Etiometry, a leader in clinical decision-support software for critical care, and Radiometer, a leading medical device company specializing in acute care testing solutions, today announced a new collaboration to enhance the clinical workflows in Neonatal Intensive Care Units (NICU).

From Radiometer Medical 12 Oct 2022

Scientists investigate the antibody titers post-mRNA COVID-19 booster vaccine in the elderly

The coronavirus 2019 disease (COVID-19) pandemic has affected millions worldwide and claimed multiple lives.

6 Oct 2022

What are the differences in transmissibility between novel and emerging SARS-CoV-2 variants?

In a new study, researchers compared the transmissibility of novel and emerging SARS-CoV-2 variants.

29 Sep 2022

Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model

In a recent study posted to the bioRxiv* server, researchers at the United States Army Medical Research Institute of Infectious Diseases evaluated the immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) deoxyribonucleic acid (DNA) vaccine, nCOV-S(JET), in rhesus macaques

18 Sep 2022

Techniques used for SARS-CoV-2 detection in body fluids

In a recent review published in the journal Trends in Analytical Chemistry, researchers provided a comprehensive overview of the current techniques used for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in bodily fluids.

7 Sep 2022

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences BV 5 Sep 2022

SARS-CoV-2 nucleocapsid antigen levels and patient outcomes

In a new study, researchers assessed the correlation between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) antigen levels and hospitalized patient outcomes.

31 Aug 2022

Wyss Institute's DNA nanotechnology-driven SPEAR protein-detection technology licensed to Spear Bio

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Spear Bio, Inc.announced that the Institute's DNA nanotechnology-driven ultrasensitive SPEAR protein-detection technology has been licensed to the newly formed Boston-based startup.

23 Aug 2022

Immunoassay News and Research

The Native Antigen Company introduces new range of influenza antigens

What were the SARS-CoV-2 seroprevalence estimates for industrial livestock operation workers in the USA for 2021-2022?

Novel troponin test may help improve the treatment of heart attack patients

SARS-CoV-2 infection can affect menstruation

What is the association of self-reported post-vaccination symptoms with anti–SARS-CoV-2 antibody response?

FebriDX point-of-care immunoassay can rapidly determine if an infection is bacterial or viral

Study finds memory B cell clones harbor the capacity to adopt multiple and functionally different fates in COVID-19 patients

Radiometer strengthens its global Immunoassay Business in Turku

Radiometer and Etiometry Announce Partnership to Enhance Neonatal Intensive Care Clinical Workflows and Patient care

Scientists investigate the antibody titers post-mRNA COVID-19 booster vaccine in the elderly

What are the differences in transmissibility between novel and emerging SARS-CoV-2 variants?

Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model

Techniques used for SARS-CoV-2 detection in body fluids

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

SARS-CoV-2 nucleocapsid antigen levels and patient outcomes

Wyss Institute's DNA nanotechnology-driven SPEAR protein-detection technology licensed to Spear Bio

Human antibody responses to SARS-CoV-2 infection after two years

Study warns of a potential Sindbis virus epidemic in 2022

Nanoparticle-based lateral flow immunoassay for the detection of anti-SARS-CoV-2 neutralizing antibodies

The safety and preliminary efficacy of OP-101 in patients with severe COVID-19

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News